Amendments to the Specification:

Please replace the 3rd full paragraph of page 8 with the following rewritten paragraph:

As used herein, the terms "molecular recognition element" or "MRE" are intended to include the component of the Modular Molecular Clasp that is capable of binding to a ligand. The MRE may be a single moiety, e.g., a polypeptide or protein domain, or it may include two or more moieties, e.g., a pair of polypeptides such as a pair of single chain antibody domains. The MRE may be derived from a naturally occurring protein or polypeptide; it may be designed de novo, or it may be selected from a library. For example, the MRE may be or derived from an antibody, a single chain antibody (scFv), a single domain antibody (VHH), a lipocalin, a single chain MHC molecule, an ~~Anticalin™~~ ANTICALIN™ (engineered protein with antibody-like binding functions derived from natural lipocalins as a scaffold, Pieris), an ~~Affibody™~~ AFFIBODY™ (highly specific affinity proteins that mimic monoclonal antibodies, and can be designed to bind to any desired target protein, Affibody), or a ~~Trinectin™~~ TRINECTIN™ (engineered protein consists of a scaffold adapted from fibronectin, and with extremely high binding specificity and affinity for target proteins, Phylos). In a preferred embodiment, the MRE is a single chain antibody.

Please replace the 2nd paragraph of page 11 with the following rewritten paragraph:

The MRE can be naturally occurring or may be non-naturally occurring or mutated from its naturally occurring DNA or protein sequence. Preferred MRE superfamilies include, but are not limited to, single chain antibodies (scFv), single domain antibodies (VHH), an ~~Anticalin™~~ ANTICALIN™ (Pieris), a lipocalin, an ~~Affibody™~~ AFFIBODY™ (Affibody), a ~~Trinectin™~~ TRINECTIN™ (Phylos), single chain T cell receptors, and single chain MHC molecules. In a preferred embodiment, the MRE is a single chain antibody. In that embodiment, the MRE comprises at least one single chain antibody VH chain (or a portion thereof) or at least one VL chain (or portion thereof) specific for a ligand of interest. In a preferred embodiment, the MRE comprises at least a portion of a VH and a portion of a VL chain that recognizes and binds to a ligand of interest and a transducer is disposed between the VH and VL chains.

Please replace the 1st full paragraph of page 25 with the following rewritten paragraph:

Methods for modeling and designing the Modular Molecular Clasps of the present invention are described in U.S. Patent Application ~~Serial No.~~ Serial No. 09/996,249, entitled "Methods and Systems for Designing Machines Including Biologically Derived Parts" by Chan J. *et al* filed on November 28, 2001, the entire contents of which are incorporated herein by reference.